Literature DB >> 15580606

Levodopa-dyskinesia incidence by age of Parkinson's disease onset.

Neeraj Kumar1, Jay A Van Gerpen, James H Bower, J Eric Ahlskog.   

Abstract

We assessed the 5-year risk of levodopa-induced dyskinesias by age of Parkinson's disease (PD) onset in a population-based cohort. The medical records linkage system of the Rochester Epidemiology project was used to identify residents of Olmsted County, Minnesota, with incident PD for the period 1976 through 1990. In this population-based study, the 5-year dyskinesia incidence declined with age. With PD onset after 70 years of age, the incidence was 16%. With onset from 40 to 59 years of age, the incidence was higher at 50%. These incidence data may overestimate the functional importance, because patients with minimal or reversible dyskinesias were counted. 2004 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15580606     DOI: 10.1002/mds.20360

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  36 in total

Review 1.  Cheaper, simpler, and better: tips for treating seniors with Parkinson disease.

Authors:  J Eric Ahlskog
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

2.  Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.

Authors:  Christopher A Lieu; Milind Deogaonkar; Roy A E Bakay; Thyagarajan Subramanian
Journal:  Parkinsonism Relat Disord       Date:  2010-11-11       Impact factor: 4.891

3.  Improving symptom control in early Parkinson's disease.

Authors:  Stuart H Isaacson; Robert A Hauser
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

4.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

5.  Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study.

Authors:  Pierpaolo Turcano; Michelle M Mielke; James H Bower; Joseph E Parisi; Jeremy K Cutsforth-Gregory; J Eric Ahlskog; Rodolfo Savica
Journal:  Neurology       Date:  2018-11-07       Impact factor: 9.910

6.  Seniors with Parkinson's disease: initial medical treatment.

Authors:  J Eric Ahlskog
Journal:  J Clin Neurol       Date:  2010-12-31       Impact factor: 3.077

7.  Peer reviewed publications in 2005.

Authors: 
Journal:  Ochsner J       Date:  2006

Review 8.  Dyskinesias and levodopa therapy: why wait?

Authors:  Michele Matarazzo; Alexandra Perez-Soriano; A Jon Stoessl
Journal:  J Neural Transm (Vienna)       Date:  2018-02-10       Impact factor: 3.575

Review 9.  [Parkinson's disease in the elderly].

Authors:  Rüdiger Lange; Frank Erbguth
Journal:  Z Gerontol Geriatr       Date:  2017-07-19       Impact factor: 1.281

Review 10.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.